Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Active not recruiting 3

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3

Conditions

Breast Neoplasms 291Carcinoma, Non-Small-Cell Lung 222Neoplasms 193Prostatic Neoplasms 158Multiple Myeloma 138Neoplasm Metastasis 115Melanoma 110Colorectal Neoplasms 107Leukemia, Myeloid, Acute 103Lymphoma 97Lung Neoplasms 94Ovarian Neoplasms 84Squamous Cell Carcinoma of Head and Neck 75Lymphoma, Non-Hodgkin 73Leukemia, Lymphocytic, Chronic, B-Cell 70Pancreatic Neoplasms 64Triple Negative Breast Neoplasms 62Myelodysplastic Syndromes 62Parkinson Disease 4, Autosomal Dominant Lewy Body 59Hematologic Neoplasms 59Head and Neck Neoplasms 59Recurrence 56Glioblastoma 55Leukemia 53Precursor Cell Lymphoblastic Leukemia-Lymphoma 52Sarcoma 49Brain Neoplasms 49Lymphoma, Large B-Cell, Diffuse 47Carcinoma, Hepatocellular 47Lymphoma, Follicular 45

Interventions

Specimen Handling 3Biopsy 3X-Rays 2trastuzumab biosimilar HLX02 1pertuzumab 1erdafitinib 1copanlisib 1Trastuzumab 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1CT-P6 12C4 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Malignant Solid Neoplasm × 1 year × Clear all
NCT06136897 2026-05-29

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
35 enrolled 10 charts
Other solid neoplasm

Malignant Solid Neoplasm

NCT06351371 2026-05-28

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
35 enrolled 10 charts
Other solid neoplasm

Malignant Solid Neoplasm

NCT06360588 2026-05-28

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
22 enrolled 9 charts
Other solid neoplasm

Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡